51. Thrombolysis In Myocardial Infarction (TIMI) Study Group
- Author
-
Mph Marc S. Sabatine and Eugene Braunwald
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Atrial fibrillation ,Thrombolysis ,030204 cardiovascular system & hematology ,medicine.disease ,Clinical trial ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Heart failure ,Antithrombotic ,medicine ,Cardiology ,cardiovascular diseases ,030212 general & internal medicine ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,Dyslipidemia ,TIMI - Abstract
In 1984, the National Heart, Lung, and Blood Institute (NHLBI) decided to study the efficacy and safety of the treatment of acute myocardial infarction with an emerging therapy, coronary thrombolysis, and thus the TIMI (Thrombolysis In Myocardial Infarction) Study Group was born. Following completion of 3 clinical trials of thrombolytic therapy supported by the NHLBI, TIMI became an academic research organization headquartered at Brigham and Women's Hospital and subsequently branched out to study a wide range of patients, including those with stable coronary, cerebrovascular, and peripheral arterial disease; dyslipidemia; heart failure; atrial fibrillation; diabetes; and obesity. TIMI also began to study a wide range of interventions including thrombolytic, antithrombotic, lipid-modifying, anti-inflammatory, heart failure, glucose-lowering, and weight loss agents. TIMI, now in its 37th year, has completed >70 trials. This review describes the origins of the TIMI Study Group, summarizes several of its completed trials and the major lessons learned from them, and discusses ongoing trials and future directions.
- Published
- 2021